Clinical Trials Browser

Interventional × Rectal Neoplasms × spartalizumab × Clear all

NCT07549399 2026-04-24

CRITⅡ

Phase 3 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT04294160 2025-12-24

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Phase 1 Terminated

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT05576480 2025-08-28

SPARC

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06507371 2025-06-26

mRCAT-III

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06908031 2025-05-14

CRIT

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06665087 2024-10-30

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

Phase 2 Not yet recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT05628038 2024-10-01

TORCH-R

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06455124 2024-06-13

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05307198 2023-10-10

RAIC

Phase 2 Unknown

Gastrointestinal

Rectal Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms